Research programme: SK potassium channel inhibitors - Acesion Pharma

Drug Profile

Research programme: SK potassium channel inhibitors - Acesion Pharma

Alternative Names: NS 309; NS 4591; NS 8593

Latest Information Update: 10 Oct 2016

Price : $50

At a glance

  • Originator NeuroSearch
  • Developer Acesion Pharma; NeuroSearch
  • Class Indoles; Oximes; Small molecules
  • Mechanism of Action Intermediate conductance calcium activated potassium channel modulators; Small conductance calcium activated potassium channel modulators; Small conductance calcium-activated potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Atrial fibrillation
  • Discontinued Chronic obstructive pulmonary disease; Epilepsy; Overactive bladder

Most Recent Events

  • 01 Oct 2016 Preclinical development is ongoing Denmark
  • 02 Dec 2013 Preclinical development is ongoing in Denmark
  • 15 Dec 2011 Research programme: SK/IK potassium channel modulators licensed to Acesion Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top